Atomico Berlin

Atomico is the European growth-stage investor that European founders measure themselves against, and its Berlin office sits at the center of the firm’s continental practice. Founded in 2006 by Niklas Zennstrom of Skype fame, the firm has spent two decades funding companies that scale across borders rather than nestle inside a single country, and the Berlin team is the connective tissue between London, the Nordics, and the German-speaking markets that produce the bulk of European deep tech. The firm’s pan-European thesis is the structural advantage. While American funds parachute in for hot rounds and local micro-funds run out of capital after Series A, Atomico writes follow-ons across multiple stages and stays through the IPO window. For an AI-enabled clinical platform building outside the US, that capital continuity is rare and meaningful.

Atomico’s healthcare thesis is best understood inside its broader deep tech mandate. The firm is not a healthcare specialist; it is a generalist growth investor that treats AI/ML in clinical workflows, digital health platforms, and life-science software as one front in a wider deep tech war. That positioning has consequences for founders. Atomico will pay up for technical depth, will tolerate longer commercialization timelines than a pure SaaS investor, and will reward teams whose moat compounds with data and model improvements rather than with sales motion alone. The flip side is that the firm wants global ambition baked in. A Berlin-based AI radiology company selling only into German hospitals is not the kind of thesis that survives an Atomico partnership conversation. The firm is looking for companies whose AI substrate works across regulatory regimes, whose customer wedge is replicable in multiple national health systems, and whose technical leadership rivals what is being built in San Francisco. Healthcare-specific regulatory expertise lives more often in the firm’s network of operating advisors than in the partnership itself, which is a feature for founders who want investors thinking about company-building rather than micromanaging clinical strategy.

Atomico has not published a dedicated healthcare portfolio carve-out, and this entry does not list specific portfolio companies, so founders should consult the firm’s website directly for current investments. What is documented in the public record is that the firm has historically backed European technology champions across consumer, enterprise software, fintech, and increasingly deep tech and applied AI, with healthcare-adjacent deals coming through the AI/ML thesis rather than a discrete vertical fund. Founders evaluating Atomico should map the partner roster against the specific subsector they are building in and look for prior board roles in adjacent regulated industries, since pattern matching across regulated verticals is often a stronger predictor of partner fit than nominal healthcare experience.

Check sizes between five and twenty-five million dollars place Atomico squarely in the Series A through Series C window, with the upper end of the range typically reserved for high-conviction follow-ons rather than first checks. The firm is not a seed shop and will rarely lead a first institutional round below three million dollars in commitment, though exceptions exist for repeat founders or unusually capital-intensive deep tech. For most healthcare AI founders, an Atomico fit emerges at Series A with revenue traction in at least one national market and a clear path to a second, or at Series B when the question shifts from product-market fit to scaling clinical deployments. The firm syndicates comfortably with American crossover funds and European growth investors, which matters because Atomico-led rounds often signal to US investors that a European company is ready for transatlantic expansion. Reserves are deep enough to defend pro-rata into late-stage rounds, which reduces the dilution drag that smaller European funds inflict on their winners.

Team member names for the Berlin office are not enumerated in the source data for this profile, and the firm’s partnership rotates between London headquarters and continental offices. Founders should confirm current Berlin investing partners through the firm’s website before reaching out, paying particular attention to which partners have led prior healthcare or applied AI rounds. The Berlin team typically serves as the originating relationship for German, Austrian, Swiss, and Eastern European deals, with London partners often joining for IC and post-investment support. Decision-making at Atomico is partnership-driven, with a single sponsoring partner shepherding a deal through internal review and committee approval, so founder energy is best spent building conviction with one champion rather than spreading thin across the partnership.

The most reliable path into Atomico is a warm introduction from a European founder already in the portfolio, ideally one whose company sits in deep tech or applied AI rather than pure consumer or fintech. Second best is a connection through one of the firm’s operating partners or its network of European technical advisors. Cold inbound through the firm’s website is read but converts at the rates typical of brand-name funds, which is to say rarely. When a Berlin partner does engage, expect a measured European pace rather than the compressed timelines of a hot Bay Area round. Diligence will go deep on technical defensibility, on the founding team’s ambition for cross-border scale, and on how the company’s wedge maps to a multi-billion-dollar market. Bring data, not narrative.

Founders should approach Atomico when they are ready to be evaluated on global ambition rather than local traction. The firm is a poor fit for companies whose market thesis ends at a single national health system or whose competitive moat depends on a regulatory carve-out unique to one country. It is an excellent fit for technical founders building AI infrastructure that happens to address clinical use cases, for digital health platforms with multi-country expansion logic, and for life-science software companies whose underlying technology is genuinely novel. If the company is still searching for its first paying customer, Atomico is too late-stage to engage. If the company has revenue in one market and a credible plan to enter two more within twenty-four months, the conversation is worth starting.